Nuvalent, Inc.
NUVL
Hisse Senetlerindeki Sıralama
#2080
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Hisse Fiyatı
$123.96
Son senkronizasyon: 2026-07-21
Piyasa Değeri
$9.75B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
36.40%
Ülke
US
Ticaret Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Nuvalent, Inc. (NUVL) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $123.86 - 2026-07-01
Gün sonu en düşük fiyat: $18.50 - 2021-07-01
Gün sonu en düşük fiyat: $18.50 - 2021-07-01
Nuvalent, Inc. için hisse fiyatı geçmişi: 2021 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 0.78% |
| 2025 | 19.50% |
| 2024 | 20.56% |
| 2023 | 136.75% |
| 2022 | 51.32% |
| 2021 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $536.73 | 25.86% |
US
|
|
| $225.94 | 741.49% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.85 | 7.94% |
NL
|
